Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Adenocarcinoma of the Body and Tail
- 214 Downloads
The prognostic impact of pancreatic ductal adenocarcinoma (PDAC) invasion to the splenic vessel is controversial.
The aim of this study was to assess the clinical value of pathological and radiological splenic vessel invasion in PDACs of the body and tail.
Medical records of patients with resectable PDAC of the body and tail who underwent distal pancreatectomy between 2003 and 2016 at the Kobe University Hospital were retrospectively analyzed.
Overall, 68 patients (29 female and 39 male patients) were enrolled. Pathologically determined splenic vein invasion (p-SV) and splenic artery invasion (p-SA) were identified in 21 (30.9%) and 5 (7.4%) patients, respectively. The p-SV (but not p-SA) was an independent prognostic factor in multivariate analysis (p = 0.009). On analysis of recurrence patterns, patients with PDAC positive for p-SV were at a higher risk for liver metastasis (p = 0.022); however, the associations were not significant for other recurrence patterns. Liver metastasis occurred earlier in patients who were positive for p-SV (p = 0.015). Preoperative computed tomography effectively diagnosed pathological vessel invasion (SV: sensitivity, 95.2%, specificity, 72.3%; SA: sensitivity, 100%, specificity, 84.1%). Radiological SV invasion remained significant in multivariate analysis regarding postoperative survival (p = 0.007), and was also associated with early liver metastases (p = 0.008).
Pathological/radiological SV invasion were independent adverse prognostic factors associated with early liver metastasis in patients with PDAC of the body/tail. Assessment of these findings may be useful in determining optimal therapeutic options in these patients.
Takuya Mizumoto, Hirochika Toyama, Sadaki Asari, Sachio Terai, Hideyo Mukubo, Hironori Yamashita, Sachiyo Shirakawa, Yoshihide Nanno, Yuki Ueda, Keitaro Sofue, Motofumi Tanaka, Masahiro Kido, Tetsuo Ajiki, and Takumi Fukumoto have no conflicts of interest to declare.
- 3.National Comprehensive Cancer Network (2017). NCCN clinical practice guidelines in oncology (NCCN Guidelines). Pancreatic adenocarcinoma. Version 1. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 10 Jan 2017.
- 15.Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. New York: Wiley; 2009.Google Scholar